



Topic of the Speech:

Testing for COVID-19 in Patient Identification, Infection Containing, Clinical Surveillance, Pandemic Prediction and Further Prevention

Dr. Liya Ju

PreciMed Platform Europe
France



Dr. Liya Ju, MD, PhD, Started her research work in China in the eighties in the field of molecular and genetic biology of nasopharyngeal cancer with Pr Dausset, Nobel Price in immunology, she joined in 86 the French public research institute INSERM in Paris and obtained her PhD in immunology at the Institute Pasteur. In 94, she joined Debiopharm, a Swiss biotech company as director of the Chinese Program, as direct assistant to the President General Director for 15 years. Her tasks were the registration of European compounds for the Chinese market (oxaliplatin, decapeptyl), identification of new Chinese molecules from biotech and traditional medicine for development in Europe and US , recognition of DebioChina brand all over China, and building an academic and biotech network serving Debiopharm.

In 2008, with this academic and industrial experience of 20 years, Dr Liya JU set up the SETRAD (Sino-European therapeutics R&D), a consulting company in the field of pharmacy, based in France with an exclusive activity in China, in order to introduce Chinese innovative compounds to occidental market, register us and European molecules in china, and help the international academic collaboration.

In 2011, she was asked by Pr Dominique Charron, director of the Jean Dausset Lab Network/HLA et Medecine at the university of Paris to join the Saint-Louis Hospital for project valorization. She continued in the research in HLA and cancer, immunogenomics, pharmacogenomics, organ transplantation and molecular signaling pathway of certain Chinese immunomodulating products. In October 2011, she was nominated as Special Representative for International collaboration and China Relation of Gustave Roussy Institute and her main missions consist to promote the highlight scientific programs of IGR-China.

From October 2016, she was in charge of the China mission for international department of Great Paris University Hospitals to coordinate the sino-franco biomedical cooperations.

She created the molecular signaling pathway platform in Jean Dausset Lab Platform and headed the studies of the molecular mechanism of natural products including the Chinese TCM drug. She contributed to the immunology system implication in pharmacogenomics and the development of multi-targeted safety product in the diseases induced by immuno-pathogenerating inflammatory disorders.

From End of 2016, she was co-founder of PreciMed Platform Europe with the mission to help medical companies in Europe and US gain greater market share and help more patients get quality treatment.